Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoadjuvant Therapy
  • Polymorphism, Genetic
  • Rectal Neoplasms

abstract

  • Specific polymorphisms in XRCC1, XPD, and TP53 were associated with increased toxicity to NT in patients with rectal cancer. The current results indicated that polymorphism screening may help tailor treatment for patients by selecting therapies with the lowest risk of toxicity, thus increasing patient compliance.

publication date

  • March 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4625921

Digital Object Identifier (DOI)

  • 10.1002/cncr.27862

PubMed ID

  • 23096768

Additional Document Info

start page

  • 1106

end page

  • 12

volume

  • 119

number

  • 5